Nonpeptidergic allosteric antagonists differentially bind to the C×CR2 chemokine receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 783-790

  De Kruijf, Petra ^a   Van Heteren, Jane ^a   Lim, Herman D ^a   Conti, Paolo G M ^b   Van Der Lee, Miranda M C ^b   Bosch, Leontien ^a   Ho, Koc Kan ^c   Auld, Douglas ^c   Ohlmeyer, Michael ^c   Smit, Martin J ^a,b   Wijkmans, Jac C H M ^b   Zaman, Guido J R ^b   Leurs, Rob ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PHARMACOPEIA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 1 (2 BROMOPHENYL) 3 [4 CYANO 1H BEZO(D)(1,2,3)TRIAZOL 7 YL]UREA; 2 [2 (1H IMIDAZOL 1 YL) 6 (OCTYLTHIO)PYRIMIDIN 4 YLAMINO]N(3 ETHOXYPROPYL) 4 METHYLPENTANAMIDE; 2 [6 BUTYL 2 [4 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZOL 1 YL]PYRIMIDIN 4 YLAMINO] 4 METHYL N (4,4,4 TRIFLUOROBUTYL)PENTANAMIDE; 5 (BENZYLTHIO) 7 (1 HYDROXYBUTAN 2 YLAMINO)THIAZOL(4,5 D)PYRIMIDIN 2 OL; 6 CHLORO 3 [3 (2,3 DICHLOROPHENYL)UREIDO] 2 HYDROXYBENZENESULFONAMIDE; BETA ARRESTIN 2; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; IODINE 125; N[2 (2,5 DIHYDRO 1H PYRROL 1 YL)ETHYL] 4 METHYL 2 [6 METHYL 2 [4 [4 (TRIFLUOROMETHOXYL)PHENYL] 1H IMIDAZOL 1 YL]PYRIMIDIN 4 YLAMINO]PENTANAMIDE; SB 265610; SB 332235; UNCLASSIFIED DRUG; VUF 10984; CARBANILAMIDE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DETERMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RECEPTOR BLOCKING; ANIMAL; BINDING COMPETITION; BINDING SITE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; DRUG ANTAGONISM; GENETIC TRANSFECTION; HUMAN; PROTEIN BINDING; RADIOASSAY; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC SITE; ANIMALS; BINDING, COMPETITIVE; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; PHENYLUREA COMPOUNDS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, INTERLEUKIN-8B; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 65649101821     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.148387     Document Type: Article

References (40)

1. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, and Strieter RM (2000) The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165:5269-5277.
2. Ajuebor MN, Zagorski J, Kunkel SL, Strieter RM, and Hogaboam CM (2004) Contrasting roles for CXCR2 during experimental colitis. Exp Mol Pathol 76:1-8.
3. Allegretti M, Cesta MC, Nano G, Bertini R, Bizzarri C, and Colotta F (2005), inventors; Dompe Spa, assignee. Amidines and derivatives thereof and pharmaceutical preparations containing them. World patent WO2005028425. 2005 Mar 31.
4. Allen SJ, Crown SE, and Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787-820.
5. Barth M, Dodey P, and Paquet JL (2002), inventors. Novel 5-cyano-1H-indole derivatives as antagonists of interleukin-8 receptors and their intermediates, pharmaceutical compositions, and use. World patent WO2002092567. 2002 May 16.
6. Baxter A, Cooper A, Kinchin E, Moakes K, Unitt J, and Wallace A (2006) Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett 16:960-963.
7. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, and Allegretti M (2006) ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 112:139-149.
8. Brakenhoff RH, Knippels EM, and van Dongen GA (1994) Optimization and simplification of expression cloning in eukaryotic vector/host systems. Anal Biochem 218:460-463.
9. Buanne P, Di Carlo E, Caputi L, Brandolini L, Mosca M, Cattani F, Pellegrini L, Biordi L, Coletti G, Sorrentino C, et al. (2007) Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol 82:1239-1246.
10. Catusse J, Liotard A, Loillier B, Pruneau D, and Paquet JL (2003) Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2. Biochem Pharmacol 65:813-821.
11. Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, et al. (2007) A novel, orally active CXCRV2 receptor antagonist, Sch527l23, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 322:486-493.
12. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
13. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265.
14. Conti P, Leysen D, Lounnas V, Ohlmeyer M, Bohnstedt AC, Ho KK, Kultgen SG, Roughton A and Auld DS (2004), inventors; Pharmacopeia Drug Discovery, assignee. (2S)-2-[(pyrimidin-4-yl)amino]-4-methylpentanoic acid aminoethylamide derivatives as interleukin 8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis. World patent WO2004069829. 2004 Aug 19.
15. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, and Hipkin RW (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59:707-715.
16. Cutshall NS, Ursino R, Kucera KA, Latham J, and Ihle NC (2001) Nicotinamide N-oxides as CXCR2 antagonists. Bioorg Med Chem Lett 11:1951-1954.
17. Donnelly LE and Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 27:546-553.
18. Erickson S, Baldwin J, Dolle RE, Inglese J, Ohlmeyer M, Ho KK, Bohnstedt AC, Kultgen SG, Conti P, Leysen D, et al. (2004), inventors. Pyrimidine derivatives as IL-8 receptor antagonists. World patent WO2004062609. 2004 Jul 29.
19. Goldman LA, Cutrone EC, Kotenko SV, Krause CD, and Langer JA (1996) Modifications of vectors pEF-BOS, pcDNAl and pcDNA3 result in improved convenience and expression. Biotechniques 21:1013-1015.
20. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, et al. (2007) Pharmacological characterization of Sch527l23, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 322:477-485.
21. Ho KK, Auld DS, Bohnstedt AC, Conti P, Dokter W, Erickson S, Feng D, Inglese J, Kingsbury C, Kultgen SG, et al. (2006) Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg Med Chem Lett 16:2724-2728.
22. Keane MP, Belperio JA, Xue YY, Burdick MD, and Strieter RM (2004) Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172:2853-2860.
23. Kulke R, Bornscheuer E, Schlüter C, Bartels J, Röwert J, Sticherling M, and Christophers E (1998) The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 110:90-94.
24. Li JJ, Carson KG, Trivedi BK, Yue WS, Ye Q, Glynn RA, Miller SR, Connor DT, Roth BD, Luly JR, et al. (2003) Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor. Bioorg Med Chem 11:3777-3790.
25. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145-176.
26. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, et al. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74:1193-1202.
27. Olson KR and Eglen RM (2007) Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol 5:137-144.
28. Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, et al. (2002) A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 169:6435-6444.
29. Rajagopalan L and Rajarathnam K (2006) Structural basis of chemokine receptor function-a model for binding affinity and ligand selectivity. Biosci Rep 26:325-339.
30. Richardson RM, Marjoram RJ, Barak LS, and Snyderman R (2003) Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J Immunol 170:2904-2911.
31. Rotondi M, Chiovato L, Romagnani S, Serio M, and Romagnani P (2007) Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28:492-520.
32. Singh S, Sadanandam A, and Singh RK (2007) Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26:453-467.
33. Thatcher TH, McHugh NA, Egan RW, Chapman RW, Hey JA, Turner CK, Redonnet MR, Seweryniak KE, Sime PJ, and Phipps RP (2005) Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 289:L322-L328.
34. Verzijl D, Pardo L, van Dijk M, Gruijthuijsen YK, Jongejan A, Timmerman H, Nicholas J, Schwarz M, Murphy PM, Leurs R, et al. (2006) Helix 8 of the viral chemokine receptor ORF74 directs chemokine binding. J Biol Chem 281:35327-35335.
35. Verzijl D, Storelli S, Scholten DJ, Bosch L, Reinhart TA, Streblow DN, Tensen CP, Fitzsimons CP, Zaman GJ, Pease JE, et al. (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther 325:544-555.
36. Viola A and Luster AD (2008) Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48:171-197.
37. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, et al. (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095-10098.
38. Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, et al. (2004) Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem 47:1319-1321.
39. Willis PA, Bonnert RV, Hunt SF and Walters IAS (2001), inventors. Novel thia-zolo[4,5-d]pyrimidines compounds. World patent WO2001025242. 2001 Apr 12.
40. Yan YX, Boldt-Houle DM, Tillotson BP, Gee MA, D'Eon BJ, Chang XJ, Olesen CE, and Palmer MA (2002) Cell-based high-throughput screening assay system for monitoring G protein-coupled receptor activation using beta-galactosidase enzyme complementation technology. J Biomol Screen 7:451-459.